TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8174987

Group type: EXPERIMENTAL
Intervention: Paroxetine 30 mg daily for five days
Number of subjects: 8

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 8
Study: 3356083

Group type: EXPERIMENTAL
Intervention: Dilevalol (group 1)
Number of subjects: 2

Group type: COMPARATOR
Intervention: Atenolol (group 1)
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Dilevalol (group 2)
Number of subjects: 2

Group type: COMPARATOR
Intervention: Metoprolol (group 2)
Number of subjects: 2
Study: 28737966

Group type: EXPERIMENTAL
Intervention: Nasal corticosteroid treatment (mometasone)
Number of subjects: 236

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 236
Study: 26694228

Group type: EXPERIMENTAL
Intervention: Strength training (ST)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Strength followed by endurance training (ST-END)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Endurance followed by strength training (END-ST)
Number of subjects: 18
Study: 25006066

Group type: COMPARATOR
Intervention: Control diet (0.21% S; CON)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: High S diet (0.51% S; HS)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: High S diet + 300 mg of ferric Fe from FAC/kg DM (HS+Fe)
Number of subjects: 18
Study: 22791090

Group type: EXPERIMENTAL
Intervention: Drotrecogin alfa (activated)
Number of subjects: 477
Study: 20608635

Group type: EXPERIMENTAL
Intervention: Proximal Femoral Nail Antirotation (PFNA)
Number of subjects: 136

Group type: COMPARATOR
Intervention: Gamma Nail 3 (GN-3)
Number of subjects: 136
Study: 18337483

Group type: EXPERIMENTAL
Intervention: tacrolimus/sirolimus
Number of subjects: 132

Group type: COMPARATOR
Intervention: mycophenolate mofetil (MMF)/sirolimus
Number of subjects: 132
Study: 16329761

Group type: EXPERIMENTAL
Intervention: high-SFA diet (20 energy %)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: high-USFA diet (24 energy %)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: high-USFA diet
Number of subjects: 20
Study: 15549368

Group type: EXPERIMENTAL
Intervention: Intermittent exercise with series (IEs)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Intermittent exercise without series (IE)
Number of subjects: 11
Study: 11095440

Group type: COMPARATOR
Intervention: Growth hormone (Humatrope, Eli Lilly & Co.) at a dose of 0.05 IU/kg/week for 1 month, then 0.1 IU/kg/week divided into daily subcutaneous injections (0.75-1.25 IU/day) for 6 months followed by 12 months of open treatment.
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo treatment for 6 months.
Number of subjects: 31
Study: 8820895

Group type: COMPARATOR
Intervention: Room air
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Nitrogen/oxygen mixture (hypoxic gas)
Number of subjects: 10
Study: 1316041

Group type: EXPERIMENTAL
Intervention: Clindamycin-gentamicin
Number of subjects: 170

Group type: COMPARATOR
Intervention: Cefoxitin-doxycycline
Number of subjects: 170
Study: 4045047

Group type: EXPERIMENTAL
Intervention: Digitalis therapy
Number of subjects: 1921

Group type: COMPARATOR
Intervention: No digitalis therapy (placebo)
Number of subjects: 1921

Group type: EXPERIMENTAL
Intervention: Digitalis therapy (adjusted)
Number of subjects: 1921

Group type: EXPERIMENTAL
Intervention: Digitalis therapy (multiple logistic regression)
Number of subjects: 1921
Study: 3040835

Group type: EXPERIMENTAL
Intervention: Prednisone (50 mg/day for 4 days)
Number of subjects: 2

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 2
Study: 31865633

Group type: EXPERIMENTAL
Intervention: U-500R via continuous subcutaneous insulin infusion (CSII)
Number of subjects: 420

Group type: COMPARATOR
Intervention: U-500R via multiple daily injections (MDI)
Number of subjects: 420
Study: 30896356

Group type: EXPERIMENTAL
Intervention: Hypohydration (HypoH)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Euhydration (EuH)
Number of subjects: 11
Study: 28532874

Group type: EXPERIMENTAL
Intervention: Kinesiology tape (KT)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Postural correction exercises
Number of subjects: 46
Study: 26168982

Group type: COMPARATOR
Intervention: Pemetrexed 500 mg/m² i.v. on day 1 of 3-week cycle
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel 150 mg/m² i.v. on days 1 and 8 of 3-week cycle
Number of subjects: 111
Study: 23248172

Group type: EXPERIMENTAL
Intervention: GLP-1 alone
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Glucagon alone
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: GLP-1 plus glucagon
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 10
Study: 21987700

Group type: EXPERIMENTAL
Intervention: Hearing conservation intervention (3-year duration)
Number of subjects: 392

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 392
Study: 18314098

Group type: EXPERIMENTAL
Intervention: Computational model of spatial visualization capacity
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Parameter-value fitting experiment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Replication experiment without further fitting
Number of subjects: 0
Study: 16848802

Group type: EXPERIMENTAL
Intervention: Esomeprazole 40 mg three times daily (t.i.d.)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Esomeprazole 40 mg twice daily (b.i.d.)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Esomeprazole 20 mg three times daily (t.i.d.)
Number of subjects: 31
Study: 11907418

Group type: EXPERIMENTAL
Intervention: Cyclosporine
Number of subjects: 8

Group type: COMPARATOR
Intervention: Tacrolimus
Number of subjects: 8
Study: 10208556

Group type: EXPERIMENTAL
Intervention: Subordinate level categorizations
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Superordinate level categorizations
Number of subjects: 0

Group type: COMPARATOR
Intervention: Basic level categorizations
Number of subjects: 0
Study: 8573841

Group type: EXPERIMENTAL
Intervention: Hemodialysis (HD)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Continuous ambulatory peritoneal dialysis (CAPD)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Full polysomnography
Number of subjects: 36

Group type: COMPARATOR
Intervention: Overnight home monitoring of nasal airflow and arterial oxygen saturation
Number of subjects: 36
Study: 1964580

Group type: EXPERIMENTAL
Intervention: visacor
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: doxazosin
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: tiapamil
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: nisoldipine
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: perindoprilat
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: dilevalol
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: carvedilol
Number of subjects: 126

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 126
Study: 642556

Group type: EXPERIMENTAL
Intervention: Autologous blood transfusion (ATS)
Number of subjects: 114

Group type: COMPARATOR
Intervention: Bank blood transfusion (control)
Number of subjects: 114
Study: 31812337

Group type: EXPERIMENTAL
Intervention: Antibiotics for ≤24 hours
Number of subjects: 704

Group type: COMPARATOR
Intervention: Antibiotics for ≥96 hours
Number of subjects: 704
Study: 29203067

Group type: EXPERIMENTAL
Intervention: Target IOP of 6 mmHg
Number of subjects: 571

Group type: EXPERIMENTAL
Intervention: Target IOP of 15 mmHg
Number of subjects: 571

Group type: EXPERIMENTAL
Intervention: Target IOP of 24 mmHg
Number of subjects: 571
Study: 26854780

Group type: EXPERIMENTAL
Intervention: Coronoid process graft (CPG)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Costochondral graft (CCG)
Number of subjects: 10
Study: 25278424

Group type: EXPERIMENTAL
Intervention: Quitline counselling
Number of subjects: 512

Group type: COMPARATOR
Intervention: Self-help brochure
Number of subjects: 512
Study: 22570108

Group type: EXPERIMENTAL
Intervention: Peer and practice team intervention (three monthly calls from trained peer patients and two practice staff visits)
Number of subjects: 280

Group type: EXPERIMENTAL
Intervention: Peer and practice team intervention
Number of subjects: 280

Group type: COMPARATOR
Intervention: Usual physician care and brochures about healthy cooking and heart disease (Control)
Number of subjects: 280
Study: 21211279

Group type: EXPERIMENTAL
Intervention: Double-catheter epidural block (group D, n = 103)
Number of subjects: 206

Group type: COMPARATOR
Intervention: Single-catheter epidural block (group S, n = 103)
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: Double-catheter epidural block (group D)
Number of subjects: 206

Group type: COMPARATOR
Intervention: Single-catheter epidural block (group S)
Number of subjects: 206
Study: 18946418

Group type: EXPERIMENTAL
Intervention: Extended anticoagulation for 18 months (INR between 2 and 3)
Number of subjects: 374

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 374
Study: 16648017

Group type: EXPERIMENTAL
Intervention: sips and gum chewing (treatment, n = 22)
Number of subjects: 66

Group type: COMPARATOR
Intervention: sips (control, n = 21)
Number of subjects: 66

Group type: COMPARATOR
Intervention: sips and accupressure wrist bracelet (placebo, n = 23)
Number of subjects: 66
Study: 14713377

Group type: EXPERIMENTAL
Intervention: Guidance from teachers
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Guidance from parents
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control group (swapped intervention)
Number of subjects: 31
Study: 10229057

Group type: EXPERIMENTAL
Intervention: ABT-418 (6 mg)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: ABT-418 (12 mg)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: ABT-418 (23 mg)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 8915564

Group type: EXPERIMENTAL
Intervention: Pimozide (3.4 ± 1.6 mg)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Haloperidol (3.5 ± 2.2 mg/day)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 1901083

Group type: EXPERIMENTAL
Intervention: 750 mg of immune globulin (IVIG) per kilogram of body weight
Number of subjects: 22

Group type: COMPARATOR
Intervention: Vehicle control (albumin)
Number of subjects: 22
Study: 6166982

Group type: EXPERIMENTAL
Intervention: Salmon calcitonin (SMC) 2.5 micrograms/h
Number of subjects: 40

Group type: COMPARATOR
Intervention: Sodium chloride (control)
Number of subjects: 40
Study: 31975558

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Voglibose
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study: 30679724

Group type: EXPERIMENTAL
Intervention: Second-generation antipsychotics (exact dosage and duration not specified)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Healthy controls (N=58)
Number of subjects: 82
Study: 28939263

Group type: EXPERIMENTAL
Intervention: Exercise group (stretching exercises)
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Combined exercise and ergonomic modification group
Number of subjects: 142

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Exercise group
Number of subjects: 142
Study: 27053773

Group type: EXPERIMENTAL
Intervention: Tacrolimus using PPD
Number of subjects: 8

Group type: COMPARATOR
Intervention: Standard of care (physician guidance)
Number of subjects: 8
Study: 23919483

Group type: EXPERIMENTAL
Intervention: Oral alcohol (1 ml/kg body weight of 94% alcohol, 0.75 g/kg)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 22048261

Group type: EXPERIMENTAL
Intervention: Yoga
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control
Number of subjects: 44

Group type: COMPARATOR
Intervention: Passive stretching
Number of subjects: 44
Study: 19632666

Group type: EXPERIMENTAL
Intervention: Expert users
Number of subjects: 48

Group type: COMPARATOR
Intervention: Novice users
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Reduced fidelity prototypes
Number of subjects: 48
Study: 18283207

Group type: EXPERIMENTAL
Intervention: CONSORT extension for nonpharmacologic treatments
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study: 15983524

Group type: EXPERIMENTAL
Intervention: NuSun sunflower oil diet
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Olive oil diet
Number of subjects: 31

Group type: COMPARATOR
Intervention: Average American diet
Number of subjects: 31
Study: 12608908

Group type: EXPERIMENTAL
Intervention: Metronidazole (MNZ)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Azithromycin (AZM)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo (Control)
Number of subjects: 40
Study: 11157431

Group type: EXPERIMENTAL
Intervention: Intensive Case Management (ICM)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Normal IQ patients
Number of subjects: 0
Study: 8866563

Group type: EXPERIMENTAL
Intervention: 200 mg troglitazone daily for 12 weeks
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: 400 mg troglitazone daily for 12 weeks
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Troglitazone (200 mg and 400 mg)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: All groups (including placebo)
Number of subjects: 42
Study: 1506638

Group type: EXPERIMENTAL
Intervention: Sclerotherapy
Number of subjects: 187
Study: 6088713

Group type: EXPERIMENTAL
Intervention: Radiotherapy 6000 rads/7 weeks plus CCNU 130 mg/M2 every 6 weeks
Number of subjects: 115

Group type: COMPARATOR
Intervention: Radiotherapy 6000 rads/7 weeks plus CCNU 75 mg/M2 day 1 plus procarbazine 100 mg/m2 days 1‐14 every 6 weeks
Number of subjects: 115
Study: 31819122

Group type: EXPERIMENTAL
Intervention: Ringer's lactate solution (40 ml/kg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 5% dextrose water (20 ml/kg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 6% tetrastarch (1000 ml)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 10% pentastarch (1000 ml)
Number of subjects: 12
Study: 29878269

Group type: EXPERIMENTAL
Intervention: Multi-ingredient protein-based supplement (30 g whey protein, 2.5 g creatine, 500 IU vitamin D, 400 mg Ca, 1500 mg n-3 polyunsaturated fatty acids) taken 2 times/day for 7 weeks
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control group (22 g maltodextrin)
Number of subjects: 27
Study: 26270469

Group type: EXPERIMENTAL
Intervention: Bleach baths
Number of subjects: 40

Group type: COMPARATOR
Intervention: Water baths
Number of subjects: 40
Study: 24650336

Group type: EXPERIMENTAL
Intervention: Whole body vibration combined with counter‐movement jumping (WBV + CMJ)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Counter‐movement jumping (CMJ)
Number of subjects: 24
Study: 21995889

Group type: EXPERIMENTAL
Intervention: Life review therapy
Number of subjects: 202

Group type: COMPARATOR
Intervention: Care as usual
Number of subjects: 202
Study: 20695770

Group type: EXPERIMENTAL
Intervention: NOMAC/E2
Number of subjects: 48

Group type: COMPARATOR
Intervention: DRSP/EE
Number of subjects: 48
Study: 17632164

Group type: EXPERIMENTAL
Intervention: 0.5 mg dutasteride daily
Number of subjects: 5597

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5597
Study: 16214599

Group type: EXPERIMENTAL
Intervention: BCG revaccination
Number of subjects: 348139

Group type: COMPARATOR
Intervention: No revaccination (Control)
Number of subjects: 348139
Study: 12123409

Group type: EXPERIMENTAL
Intervention: Low MAP goal (92 mm Hg or less)
Number of subjects: 1094

Group type: COMPARATOR
Intervention: Usual MAP goal (102 to 107 mm Hg)
Number of subjects: 1094
Study: 10654116

Group type: EXPERIMENTAL
Intervention: Behavioral Family Management with Standard Dose medication (BFMSD)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Behavioral Family Management with Targeted Medication (BFMTM)
Number of subjects: 51
Study: 7966893

Group type: EXPERIMENTAL
Intervention: Purified split‐virion vaccine (n = 927)
Number of subjects: 1838

Group type: COMPARATOR
Intervention: Intramuscular placebo (n = 911)
Number of subjects: 1838
Study: 3426975

Group type: EXPERIMENTAL
Intervention: Trained doctors (communication skills programme)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Untrained general practitioners
Number of subjects: 0
Study: 29788791

Group type: EXPERIMENTAL
Intervention: Standard transdermal nicotine (nicotine replacement therapy)
Number of subjects: 499

Group type: EXPERIMENTAL
Intervention: Extended nicotine replacement therapy + adjunct nicotine agent
Number of subjects: 499

Group type: EXPERIMENTAL
Intervention: Varenicline
Number of subjects: 499

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 499
Study: 26755405

Group type: EXPERIMENTAL
Intervention: Stabilization exercises plus manual therapy
Number of subjects: 102

Group type: COMPARATOR
Intervention: Stabilization exercises alone
Number of subjects: 102
Study: 24894701

Group type: EXPERIMENTAL
Intervention: 3'‐aminomethylnicotine Pseudomonas aeruginosa r‐Exoprotein‐conjugated vaccine (400 μg/ml)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 22680238

Group type: EXPERIMENTAL
Intervention: Closed-loop stimulation (CLS)
Number of subjects: 36
Study: 20160441

Group type: EXPERIMENTAL
Intervention: 1.5 g dentifrice containing 1,100 microg/g fluoride
Number of subjects: 0

Group type: COMPARATOR
Intervention: 0.5 g dentifrice containing 1,100 microg/g fluoride
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Brushing time of 30, 45, 60, 120, and 180 seconds with 1.5 g dentifrice
Number of subjects: 0
Study: 19019662

Group type: EXPERIMENTAL
Intervention: Midazolam (0.1 mg/kg bolus, 0.04 mg/kg/hr continuous, adjusted every 2 hours)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Buprenorphine (0.625 microg kg(‐1) hr(‐1))
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 22
Study: 15818694

Group type: EXPERIMENTAL
Intervention: Etanercept (25 mg twice weekly) for 1 year
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo for 6 months before switching to etanercept
Number of subjects: 40
Study: 12463111

Group type: EXPERIMENTAL
Intervention: 64 grams/day of walnuts in conjunction with the low-fat, low-cholesterol diet
Number of subjects: 67

Group type: COMPARATOR
Intervention: Low-fat, low-cholesterol diet without walnuts
Number of subjects: 67
Study: 10516937

Group type: EXPERIMENTAL
Intervention: 1 mg tacrolimus capsules
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: 5 mg tacrolimus capsules
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: 5 mg tacrolimus doses administered at 7-day intervals
Number of subjects: 32
Study: 8880373

Group type: EXPERIMENTAL
Intervention: Electrodermal lability in hypertensive group
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control group (normotensive)
Number of subjects: 39
Study: 2060560

Group type: EXPERIMENTAL
Intervention: Dexfenfluramine 30 mg per day for 4 days
Number of subjects: 17
Study: 6834501

Group type: EXPERIMENTAL
Intervention: Meatal care with poly-antibiotic ointment twice daily
Number of subjects: 428

Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 428

Group type: EXPERIMENTAL
Intervention: Meatal care with poly-antibiotic ointment
Number of subjects: 428

Group type: EXPERIMENTAL
Intervention: Meatal care with poly-antibiotic ointment in high-risk female patients
Number of subjects: 428
Study: 31892661

Group type: EXPERIMENTAL
Intervention: Breathing exercise programme in addition to usual care (BrEX + UC)
Number of subjects: 190

Group type: COMPARATOR
Intervention: Usual care (UC) alone
Number of subjects: 190
Study: 27589017

Group type: EXPERIMENTAL
Intervention: Walking Away from Type 2 Diabetes intervention group
Number of subjects: 808

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 808
Study: 27445317

Group type: EXPERIMENTAL
Intervention: High cut-off (HCO) dialysis
Number of subjects: 43

Group type: COMPARATOR
Intervention: High-flux dialysis
Number of subjects: 43
Study: 24718885

Group type: EXPERIMENTAL
Intervention: XELOX (capecitabine plus oxaliplatin)
Number of subjects: 113

Group type: COMPARATOR
Intervention: Observation
Number of subjects: 113
Study: 22433499

Group type: EXPERIMENTAL
Intervention: Yoga intervention plus usual care
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care alone
Number of subjects: 0
Study: 19435491

Group type: EXPERIMENTAL
Intervention: Intensive treatment (IT) following screening
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Routine care (RC) following screening
Number of subjects: 63

Group type: COMPARATOR
Intervention: No screening (control)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Intensive treatment (IT)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Routine care (RC)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Screening programme
Number of subjects: 63
Study: 17264015

Group type: EXPERIMENTAL
Intervention: High-fidelity model training (n = 14)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Low-fidelity model training (n = 13)
Number of subjects: 27
Study: 15095072

Group type: EXPERIMENTAL
Intervention: High-Intensity Training (HIT)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Low-Intensity Training (LIT)
Number of subjects: 81
Study: 11266417

Group type: EXPERIMENTAL
Intervention: Azithromycin (10 mg/kg/24 h for 3 days)
Number of subjects: 118

Group type: COMPARATOR
Intervention: Co-amoxiclav (45/11.25 mg/kg/24 h for 10 days)
Number of subjects: 118
Study: 9835466

Group type: EXPERIMENTAL
Intervention: Subcutaneous buffered lidocaine (SQBL)
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Subcutaneous normal saline with 0.9% benzyl alcohol (SQNS)
Number of subjects: 103

Group type: COMPARATOR
Intervention: No pretreatment (NPTx)
Number of subjects: 103
Study: 7656458

Group type: EXPERIMENTAL
Intervention: Systemic lupus erythematosus patients (16-59 years)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Systemic lupus erythematosus patients (16-29 years)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Systemic lupus erythematosus patients (60-69 years)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 40
Study: 2180337

Group type: EXPERIMENTAL
Intervention: Early cholecystectomy
Number of subjects: 269

Group type: COMPARATOR
Intervention: Delayed cholecystectomy
Number of subjects: 269
Study: 7001488

Group type: EXPERIMENTAL
Intervention: Silderm (triamcinolone acetonide, neomycin sulphate, undecenoic acid)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Other cream (triamcinolone acetonide, neomycin sulphate, nystatin, gramicidin)
Number of subjects: 52
Study: 30521040

Group type: EXPERIMENTAL
Intervention: CEASE intervention
Number of subjects: 10

Group type: COMPARATOR
Intervention: Usual care control
Number of subjects: 10